AMGN Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 1/6 |
Dividends | 5/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$276.65
Updated
Amgen Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$270.90 |
52 Week High | US$329.72 |
52 Week Low | US$211.71 |
Beta | 0.58 |
1 Month Change | -4.51% |
3 Month Change | -2.71% |
1 Year Change | 15.41% |
3 Year Change | 8.49% |
5 Year Change | 45.18% |
Change since IPO | 192,540.00% |
Recent News & Updates
Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Recent updates
Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Sep 22Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?
Sep 04Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Aug 05Amgen Inc. (NASDAQ:AMGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 30Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year
May 09These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Reasonably Well
Apr 29Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Apr 05Amgen Inc. (NASDAQ:AMGN) Shares Could Be 37% Below Their Intrinsic Value Estimate
Feb 27Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.13
Feb 02Shareholder Returns
AMGN | US Biotechs | US Market | |
---|---|---|---|
7D | -1.6% | -2.1% | 0.5% |
1Y | 15.4% | 9.7% | 29.0% |
Return vs Industry: AMGN exceeded the US Biotechs industry which returned 9.7% over the past year.
Return vs Market: AMGN underperformed the US Market which returned 29% over the past year.
Price Volatility
AMGN volatility | |
---|---|
AMGN Average Weekly Movement | 3.3% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMGN has not had significant price volatility in the past 3 months.
Volatility Over Time: AMGN's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | 26,700 | Bob Bradway | https://www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
AMGN fundamental statistics | |
---|---|
Market cap | US$145.18b |
Earnings (TTM) | US$6.72b |
Revenue (TTM) | US$28.19b |
21.6x
P/E Ratio5.2x
P/S RatioIs AMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AMGN income statement (TTM) | |
---|---|
Revenue | US$28.19b |
Cost of Revenue | US$8.42b |
Gross Profit | US$19.78b |
Other Expenses | US$13.06b |
Earnings | US$6.72b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 12.53 |
Gross Margin | 70.15% |
Net Profit Margin | 23.83% |
Debt/Equity Ratio | 1,036.8% |
How did AMGN perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield68%
Payout RatioDoes AMGN pay a reliable dividends?
See AMGN dividend history and benchmarksAmgen dividend dates | |
---|---|
Ex Dividend Date | May 16 2024 |
Dividend Pay Date | Jun 07 2024 |
Days until Ex dividend | 58 days |
Days until Dividend pay date | 80 days |
Does AMGN pay a reliable dividends?
See AMGN dividend history and benchmarks